Fennec posts record FY2025 PEDMARK sales $44.6M (+50% YoY); Q4 $13.8M (+75%)

FENNEC PHARMACEUTICALS INC.

Full-year net product sales $44.6M vs $29.6M in 2024; Q4 $13.8M vs $7.9M in prior year.
Net loss $10.1M in FY2025 vs $0.4M in 2024, driven by higher G&A and a $2.0M loss on debt extinguishment.
Cash $36.7M at year-end; zero debt after paying down $21.5M term loan in Nov 2025.
Completed oversubscribed equity offerings raising $42.0M net; expanded commercial team.
Positive topline results from Japan trial; two institution-led studies initiated in testicular cancer and AYA patients.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

FENNEC PHARMACEUTICALS INC. reported the fiscal year ended December 31, 2025 results: revenue approximately $44.6 million.

Period: the fiscal year ended December 31, 2025
Revenue: approximately $44.6 million
Result: reported results

Exact text from the filing

For the full fiscal year (FY) 2025, the Company recorded net product sales of approximately $44.6 million compared to $29.6 million in 2024, representing an increase of approximately 50%.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

FENNEC PHARMACEUTICALS INC. reported the fourth quarter of 2025 results: revenue $13.8 million.

Period: the fourth quarter of 2025
Revenue: $13.8 million
Result: reported results

Exact text from the filing

For the fourth quarter of 2025, the Company recorded net product sales of $13.8 million compared to $7.9 million in the fourth quarter of 2024, representing an increase of approximately 75%.

View on SEC.gov

Browse all earnings releases →

FENNEC PHARMACEUTICALS INC. filing history →

Source: SEC EDGAR

accession 0001104659-26-033885

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.